GlassScriptPhysician profile
Inna I Geyler
NPI 1184649592
$9,090.50
in general payments reported to CMS, 2019-2025
35 companies · $900 in 2025
The $900 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,822 · 2020: $1,235 · 2021: $1,323 · 2022: $767 · 2023: $1,698 · 2024: $1,347 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,945.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,944.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,047.81 | 2019-2025 | |
| Amgen INC. | $1,199.84 | 2019-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $1,106.45 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $1,001.24 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $586.27 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $406.05 | 2020-2024 | Trulance, Xifaxan |
| Amarin Pharma, INC. | $370.68 | 2019-2022 | |
| Lilly USA, LLC | $304.50 | 2019-2023 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $216.13 | 2019-2024 | Airsupra, Breztri |
| Pfizer INC. | $190.16 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $176.51 | 2020-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $174.95 | 2023 | Cd Horizon Spinal System |
| Allergan, INC. | $163.34 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $125.00 | 2025 | Zenpep |
| Optinose US, INC. | $122.39 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $114.60 | 2020-2022 | |
| Alkermes, INC. | $107.48 | 2025 | Lybalvi |
| Ardelyx, INC. | $93.26 | 2024 | Ibsrela |
| Shield Therapeutics INC | $66.96 | 2023-2025 | Accrufer |
| Merck Sharp & Dohme LLC | $64.18 | 2019-2024 | |
| Esperion Therapeutics, INC. | $47.66 | 2024-2025 | Nexletol |
| Vifor Pharma, INC. | $43.33 | 2019 | |
| Vistapharm, INC. | $43.01 | 2021 | |
| Exact Sciences Corporation | $41.79 | 2023-2024 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $40.14 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $32.59 | 2020-2024 | Zoryve |
| Janssen Pharmaceuticals, INC | $28.95 | 2020 | |
| Gilead Sciences, INC. | $28.05 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.50 | 2021 | |
| Novo Nordisk INC | $22.96 | 2025 | Ozempic |
| Avanir Pharmaceuticals, INC. | $21.94 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.67 | 2019 | |
| Nestle Healthcare Nutrition INC. | $20.50 | 2021 | |
| Endo Pharmaceuticals INC. | $19.23 | 2020 | |
| Idorsia Pharmaceuticals US INC | $17.38 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inna Geyler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.